| Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ... Haematologica 106 (4), 978, 2021 | 181 | 2021 |
| Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma MD Jain, H Zhao, X Wang, R Atkins, M Menges, K Reid, K Spitler, ... Blood, The Journal of the American Society of Hematology 137 (19), 2621-2633, 2021 | 165 | 2021 |
| Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia A Emadi, R Faramand, B Carter‐Cooper, S Tolu, LA Ford, RG Lapidus, ... American journal of hematology 90 (5), E77-E79, 2015 | 111 | 2015 |
| Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes E Roselli, R Faramand, ML Davila The Journal of Clinical Investigation 131 (2), 2021 | 69 | 2021 |
| Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia AT Fathi, SA Wander, R Faramand, A Emadi Seminars in hematology 52 (3), 165-171, 2015 | 60 | 2015 |
| Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel R Faramand, M Jain, V Staedtke, H Kotani, R Bai, K Reid, SB Lee, ... Clinical Cancer Research 26 (18), 4823-4831, 2020 | 57 | 2020 |
| Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma MD Jain, B Ziccheddu, CA Coughlin, R Faramand, AJ Griswold, KM Reid, ... Blood, The Journal of the American Society of Hematology 140 (5), 491-503, 2022 | 47 | 2022 |
| Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma JM Logue, LC Peres, H Hashmi, CM Colin-Leitzinger, AM Shrewsbury, ... Blood Advances 6 (24), 6109-6119, 2022 | 40 | 2022 |
| The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis A Ghobadi, M Slade, H Kantarjian, J Alvarenga, I Aldoss, KA Mohammed, ... Blood, The Journal of the American Society of Hematology 140 (20), 2101-2112, 2022 | 34 | 2022 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 32 | 2020 |
| A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation N Bejanyan, JA Pidala, X Wang, R Thapa, T Nishihori, H Elmariah, ... Blood Advances 5 (5), 1154-1163, 2021 | 29 | 2021 |
| Increased infections and delayed CD4+ T cell but faster B cell immune reconstitution after post-transplantation cyclophosphamide compared to conventional GVHD prophylaxis in … F Khimani, P Ranspach, H Elmariah, J Kim, J Whiting, T Nishihori, ... Transplantation and Cellular Therapy 27 (11), 940-948, 2021 | 28 | 2021 |
| Sarcopenia and low muscle radiodensity associate with impaired FEV1 in allogeneic haematopoietic stem cell transplant recipients A Mishra, KD Bigam, M Extermann, R Faramand, K Thomas, JA Pidala, ... Journal of cachexia, sarcopenia and muscle 11 (6), 1570-1579, 2020 | 21 | 2020 |
| Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell … F Khimani, M Dutta, R Faramand, T Nishihori, AP Perez, E Dean, ... Transplantation and Cellular Therapy 27 (7), 620. e1-620. e9, 2021 | 18 | 2021 |
| Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide H Elmariah, SMH Naqvi, J Kim, T Nishihori, A Mishra, L Perez, ... Bone marrow transplantation 56 (7), 1683-1690, 2021 | 17 | 2021 |
| Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: preclinical and phase I trial results J Pidala, K Walton, H Elmariah, J Kim, A Mishra, N Bejanyan, T Nishihori, ... Clinical Cancer Research 27 (10), 2712-2722, 2021 | 14 | 2021 |
| Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study JD Sandoval-Sus, R Faramand, J Chavez, S Puri, P Parra, L Sokol, ... Leukemia & lymphoma 60 (2), 309-316, 2019 | 14 | 2019 |
| Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy MD Jain, B Ziccheddu, CA Coughlin, R Faramand, AJ Griswold, KM Reid, ... Blood 138, 42, 2021 | 12 | 2021 |
| Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis AC Wood, AP Perez, B Arciola, K Patel, G Johnson, E DiMaggio, ... Transplantation and cellular therapy 28 (12), 829. e1-829. e8, 2022 | 11 | 2022 |
| Toxicities associated with adoptive cellular therapies DK Hansen, M Dam, RG Faramand Best Practice & Research Clinical Haematology 34 (3), 101287, 2021 | 11 | 2021 |
